For the initial treatment of venous thromboembolism: Are all low-molecular-weight heparin compounds the same?

Thrombosis Research

Volumn 100, Issue 2, 2000, Pages 121-130

  Van der Heijden, Jeroen F ^a   Prins, Martin H ^a   Büller, Harry R ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Initial treatment; Low molecular weight heparin; Meta analysis; Meta regression; Unfractionated heparin; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; CERTOPARIN; CY 222; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; THROMBIN INHIBITOR; TINZAPARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; HUMAN; MEDICAL LITERATURE; META ANALYSIS; PRIORITY JOURNAL; REGRESSION ANALYSIS; THROMBOEMBOLISM; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 0034667833     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0049-3848(00)00272-3     Document Type: Article

References (55)

1. Anticoagulant drugs in the treatment of pulmonary embolism: A controlled trial
2. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis
3. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence
4. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis
5. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis
6. The heparin-antithrombin system: A natural anticoagulant mechanism
7. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
8. Heparin
9. Low-molecular-weight heparins in venous and arterial thrombotic disease
10. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
11. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin
12. Diagnosis of heparin-induced thrombocytopenia. Still a journey, not yet a destination
13. Low-molecular-weight heparins
14. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency
15. Bias in meta-analysis detected by a simple, graphical test
16. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis
17. Subcutaneous KABI 2165 in the treatment of deep vein thrombosis of the leg
18. Fixed dose LMW heparin (CY216) as compared with adjusted dose intravenous heparin in the initial treatment of symptomatic proximal venous thrombosis
19. A randomized double-blind trial of low-molecular-weight heparin in the initial treatment of proximal venous thrombosis
20. A multicenter clinical trial comparing once daily and twice-daily subcutaneous enoxaparin and intravenous heparin in the treatment of acute deep vein thrombosis
21. Efficacy and safety of a low molecular weight heparin (LMW-heparin Sandoz) in patients with deep vein thrombosis
22. Efficacy and safety of a low molecular weight heparin (enoxaparin) and unfractionated heparin in proximal deep vein thrombosis
23. Fragmin once daily versus continous infusion heparin in the treatment of DVT: A European multicentre trial
24. Subcutanous administration of a low molecular weight heparin (CY 222) compared with subcutaneous administration of standard heparin in patients with acute deep vein thrombosis
25. Low molecular weight heparin (Fragmin) once daily vs. continuous infusion of standard heparin in the treatment of DVT
26. Treatment of deep venous thrombosis by fixed doses of a low-molecular-weight heparin (CY216)
27. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study
28. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis
29. Clinical experiences in the administration of a low molecular weight heparin (Fragmin, Kabi-Vitrum) to healthy volunteers and in the treatment of established deep venous thrombosis
30. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT)
31. Dose adjusted heparin treatment of deep venous thrombosis: A comparison of unfractionated and low molecular weight heparin
32. Subcutaneous heparin treatment of deep venous thrombosis: A comparison of unfractionated and low molecular weight heparin
33. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin
34. Traitment des thromboses veineuses profondes constituees: Etude comperative d'un fragment d'heparine de bas poids moleculaire (Fragmine) administree par voie sous-cutanee et de l'heparine standard administree par voie intraveineuse continue
35. Deep vein thrombosis of the legs: New therapy by means of low molecular weight heparins
36. Antithrombotic therapy in phlebopathies of lower limbs: A controlled study of low molecular weight heparin versus heparin calcium
37. Low molecular weight heparin in the short and longterm treatment of deep vein thrombosis in diabetic subjects
38. Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis
39. Low-molecular-weight heparin vs. heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group
40. Un nouveau traitement des thromboses veineuses profondes: Les fractions d'heparine de bas poids moleculaire. Etude randomisee
41. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study
42. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis
43. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: A Polish multicenter trial
44. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
45. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis
46. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis
47. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis
48. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group
49. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
50. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis
51. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire
52. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism
53. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group
54. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis
55. Treatment of acute DVT with the low molecular weight heparin (LMWH) Reviparin: Results of the CORTES-study